When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BHVN - Rhythm's Setmelanotide Data And Other News: The Good Bad And Ugly Of Biopharma
Biohaven Pharmaceutical Holding Company Ltd.
Rhythm Pharmaceuticals Reports Positive Phase 2 Data for Setmelanotide
Rhythm Pharmaceuticals Inc. (RYTM) announced interim data from its Phase 2 study of Setmelanotide. Under this trial, healthy obese people were administered the weekly formulation of the drug candidate. The trial was designed to evaluate pharmacokinetics and the safety and tolerability of the weekly formulation of setmelanotide and its impact on decreasing body weight in healthy individuals with a body mass index (NYSE:BMI) of 40 kg/m2 or greater.
The interim data analysis showed that weekly dose of setmelanotide allowed healthy obese volunteers